Special Authority Forms
General Practitioners and specialists can download individual forms for making Special Authority applications from this page.
Alternatively, all forms are available in one indexed document, Special Authority Forms, November 2008 (157 pages, 438 KB).
Find Exceptional Circumstances (EC) forms.
Sort by Therapeutic Group or Form Title (Chemical Name)
Alimentary Tract and Metabolism
From page 25 of the Pharmaceutical Schedule, November 2008 (224 pages, 1351 KB)- SA0925 – Acarbose (1 page, 2 KB)
- SA0915 – Alpha Tocopheryl Acetate (1 page, 2 KB)
- SA0913 – Budesonide – Cap 3 mg Controlled Release (1 page, 3 KB)
- SA0473 - Imiglucerase (Cerezyme) therapy - initial application (6 pages, 72 KB)
- SA0473 - Imiglucerase (Cerezyme) therapy - renewal application (4 pages, 67 KB)
- SA0834 – Insulin Glargine (1 page, 3 KB)
- SA0891 – Macrogol 3350 (1 page, 2 KB)
- SA0859 – Pioglitazone (2 pages, 6 KB)
- SA0914 – Ursodeoxycholic Acid – Cap 300 mg (1 page, 3 KB)
Blood and Blood Forming Organs
From page 40 of the Pharmaceutical Schedule, November 2008 (224 pages, 1351 KB)- SA0788 – Atorvastatin (1 page, 4 KB)
- SA0867 – Clopidogrel (3 pages, 8 KB)
- SA0930 – Dipyridamole Tab 25 mg (1 page, 3 KB)
- SA0929 – Dipyridamole Tab long-acting 150 mg (1 page, 3 KB)
- SA0922 – Erythropoietin (1 page, 3 KB)
- SA0796 – Ezetimibe (2 pages, 5 KB)
- SA0826 – Ezetimibe with Simvastatin: Vytorin (1 page, 4 KB)
- SA0932 – Pravastatin (1 page, 2 KB)
Cardiovascular System
From page 53 of the Pharmaceutical Schedule, November 2008 (224 pages, 1351 KB)- SA0933 – Candesartan (1 page, 3 KB)
- SA0911 – Losartan with or without hydrochlorothiazide (1 page, 2 KB)
- SA0934 – Midodrine (1 page, 3 KB)
- SA0256 – Perhexiline Maleate (1 page, 2 KB)
Dermatologicals
From page 62 of the Pharmaceutical Schedule, November 2008 (224 pages, 1351 KB)- SA0923 – Imiquimod (1 page, 3 KB)
Genito-Urinary System
From page 72 of the Pharmaceutical Schedule, November 2008 (224 pages, 1351 KB)- SA0928 – Finasteride (1 page, 2 KB)
Hormone Preparations - Systemic Excluding Contraceptive Hormones
From page 78 of the Pharmaceutical Schedule, November 2008 (224 pages, 1351 KB)- SA0797 – Alendronate: Alendronate Tab 70 mg (1 page, 4 KB)
- SA0835 – Buserelin (2 pages, 6 KB)
- SA0175 – Cabergoline (1 page, 2 KB)
- SA0090 – Desmopressin – Inj 4 µg per ml, 1 ml (1 page, 2 KB)
- SA0839 – Goserelin (2 pages, 6 KB)
- SA0755 - Growth hormone therapy guidelines and application forms (20 pages, 764 KB)
- SA0312 – Hormone Replacement Therapy – Systemic (1 page, 3 KB)
- SA0837 – Leuprorelin (2 pages, 6 KB)
- SA0091 – Pamidronate Disodium (1 page, 2 KB)
Infections - Agents for Systemic Use
From page 89 of the Pharmaceutical Schedule, November 2008 (224 pages, 1351 KB)- SA0829 – Adefovir dipivoxil (1 page, 3 KB)
- SA0779 – Antiretrovirals (2 pages, 6 KB)
- SA0657 – Clarithromycin (1 page, 3 KB)
- SA0845 – Enfuvirtide (1 page, 3 KB)
- SA0832 – Lamivudine (2 pages, 6 KB)
Musculo-skeletal System
From page 101 of the Pharmaceutical Schedule, November 2008 (224 pages, 1351 KB)- SA0812 – Adalimumab (2 pages, 7 KB)
- SA0291 – Anti-inflammatory Non Steroidal Drugs (NSAIDs) (1 page, 2 KB)
- SA0868 – Etanercept (1 page, 4 KB)
Nervous System
From page 106 of the Pharmaceutical Schedule, November 2008 (224 pages, 1351 KB)- SA0920 – Aripiprazole (1 page, 2 KB)
- SA0863 – Buspirone Hydrochloride (1 page, 2 KB)
- SA0907 – Dexamphetamine Sulphate (3 pages, 8 KB)
- SA0938 – Domperidone (1 page, 2 KB)
- SA0935 – Fentanyl patches (1 page, 2 KB)
- SA0936 – Gabapentin (2 pages, 6 KB)
- SA0939 – Hyoscine (Scopolamine) (1 page, 2 KB)
- SA0921 – Levetiracetam (3 pages, 114 KB)
- SA0906 – Lignocaine with Prilocaine (1 page, 2 KB)
- SA0908 – Methylphenidate Hydrochloride (Rubifen and Rubifen SR) (3 pages, 8 KB)
- SA0864 – Mianserin Hydrochloride (1 page, 2 KB)
- SA0855 – Multiple Sclerosis treatments, Initial Application for beta-interferon or glatiramer acetate (8 pages, 188 KB)
- SA0855 – Multiple Sclerosis treatments, Renewal Application form for beta-interferon or glatiramer acetate (5 pages, 176 KB)
- SA0909 – Naltrexone (1 page, 3 KB)
- SA0741 – Olanzapine tabs (1 page, 3 KB)
- SA0739 – Olanzapine wafers (1 page, 2 KB)
- SA0887 – Ondansetron (1 page, 2 KB)
- SA0926 – Risperidone microspheres (1 page, 3 KB)
- SA0927 – Risperidone orally disintegrating tablets (1 page, 2 KB)
- SA0789 – Venlafaxine (1 page, 3 KB)
- SA0937 – Vigabatrin (2 pages, 6 KB)
Oncology Agents and Immunosuppressants
From page 131 of the Pharmaceutical Schedule, November 2008 (224 pages, 1351 KB)- SA0879 – Anagrelide Hydrochloride (1 page, 3 KB)
- SA0810 – Anastrozole (1 page, 3 KB)
- SA0941 – Bicalutamide (1 page, 2 KB)
- SA0869 – Capecitabine (1 page, 3 KB)
- SA0470 – Cyclosporin A (2 pages, 5 KB)
- SA0880 – Docetaxel (2 pages, 4 KB)
- SA0877 – Gemcitabine Hydrochloride (1 page, 3 KB)
- SA0643 – Imatinib mesylate for treatment of chronic myeloid leukaemia or gastrointestinal stromal tumour (GIST) (3 pages, 40 KB)
- SA0784 – Interferon Alpha-2A with ribavirin (1 page, 2 KB)
- SA0878 – Irinotecan (1 page, 2 KB)
- SA0811 – Letrozole (1 page, 2 KB)
- SA0893 – Mycophenolate (1 page, 2 KB)
- SA0563 – Octreotide (somatostatin analogue) (1 page, 3 KB)
- SA0900 – Oxaliplatin (1 page, 3 KB)
- SA0802 – Pegylated Interferon Alpha-2a (1 page, 3 KB)
- SA0846 – Pegylated Interferon Alpha-2b with Ribavirin (1 page, 3 KB)
- SA0884 – Rituximab (2 pages, 4 KB)
- SA0866 – Sirolimus (Rapamune) (1 page, 2 KB)
- SA0669 – Tacrolimus (1 page, 2 KB)
- SA0831 – Temozolomide (1 page, 2 KB)
- SA0882 – Thalidomide (1 page, 3 KB)
- SA0885 – Trastuzumab (1 page, 3 KB)
- SA0901 – Vinorelbine (1 page, 3 KB)
Respiratory System and Allergies
From page 149 of the Pharmaceutical Schedule, November 2008 (224 pages, 1351 KB)- SA0838 – Budesonide with eformoterol (Symbicort); and Fluticasone with Salmeterol (Seretide) (1 page, 3 KB)
- SA0611 – Dornase Alfa - Entry and Stopping Criteria for Treatment (17 pages, 403 KB)
- SA0872 – Tiotropium Bromide (1 page, 3 KB)
Sensory Organs
From page 156 of the Pharmaceutical Schedule, November 2008 (224 pages, 1351 KB)- SA0895 – Pilocarpine – Eye drops 2% single dose (1 page, 2 KB)
Various
From page 161 of the Pharmaceutical Schedule, November 2008 (224 pages, 1351 KB)Extemporaneously Compounded Preparations and Galenicals
From page 166 of the Pharmaceutical Schedule, November 2008 (224 pages, 1351 KB)Special Foods
From page 169 of the Pharmaceutical Schedule, November 2008 (224 pages, 1351 KB)- SA0585 – Adult Products High Calorie: Two Cal HN (2 pages, 5 KB)
- SA0581 – Carbohydrate and Fat: Duocal Super Soluble Powder (2 pages, 4 KB)
- SA0588 – CORD Products: Pulmocare (1 page, 3 KB)
- SA0594 – Diabetic Products: Diasip, Diason, Glucerna, Glucerna RTH, Resource Diabetic, Resource Diabetic RTH (1 page, 3 KB)
- SA0615 – Fat Modified Products: Monogen (1 page, 2 KB)
- SA0899 – Fat: Calogen, Liquigen, MCT oil (Nutricia) (2 pages, 4 KB)
- SA0732 – Foods used for Homocystinuria or maple syrup urine disease: Maxamaid MSUD, Maxamum MSUD, MSUD Aid, XMET Maxamum (1 page, 2 KB)
- SA0589 – High Protein Products: Fortimel (1 page, 3 KB)
- SA0604 – Infant Formulae – For Milk Intolerance: Delact, S26 Soy, Karicare Goats Milk Infant Formula (1 page, 3 KB)
- SA0601 – Infant Formulae – For Williams Syndrome: Locasol (1 page, 2 KB)
- SA0757 – Infant Formulae – Lactose Intolerance and Cows’ Milk Protein Intolerance: Karicare All Ages (1 page, 2 KB)
- SA0600 – Multivitamin And Mineral Supplements For Inborn Errors Of Metabolism: Ketovite, Ketovite Syrup, Paediatric Seravite (1 page, 2 KB)
- SA0582 – Protein: Promod, Protifar 90 (1 page, 2 KB)
- SA0587 – Renal Products: Nepro (vanilla), NovaSource Renal, Nutrison Concentrated RTH, Renilon 7.5 (1 page, 3 KB)
- SA0592 – Specialised And Elemental Products: Alitraq, Elemental 028 Extra, Peptisorb RTH, Vital HN, Vivonex TEN (1 page, 3 KB)
Data
Active Special Authority numbers for atorvastatin (Lipitor) (2 pages, 489 KB) – listing of active Special Authority approvals for atorvastatin (Lipitor) from 1 June 2004 (other than approvals under the new criteria).
Special Authority approvals for atorvastatin (Lipitor) (40 pages, 828 KB)) – from 1 June 2004 (other than approvals under the new criteria).
Page updated on 19 Nov 2008
Linked documents
Special Authority Forms, November 2008 (157 pages, 438 KB)
SPECIAL AUTHORITY FORMS November 2008 Contents Panel Approvals… 4 Alimentary Tract and Metabolism … 5 Blood and Blood Forming Organs…. 14 Cardiovascular System ….. 26 Dermatologicals …. 31 Genito-Urinary System… 33 Hormone Preparations - Systemic Excluding Contraceptive Hormones… 36 Infections…
Pharmaceutical Schedule, November 2008 (224 pages, 1351 KB)
Introducing PHARMAC 2 November 2008 Volume 15 Number 2 Editors Linda Wellington & Julie Lagan email: schedule@pharmac.govt.nz Telephone +64 4 460 4990 Facsimile +64 4 460 4995 Level 14, Cigna House 40 Mercer Street PO Box 10 254 Wellington Freephone…
SA0473 - Imiglucerase (Cerezyme) therapy - initial application (6 pages, 72 KB)
Initial application form for imiglucerase (Cerezyme) therapy Send completed applications to: Gaucher Panel Co-ordinator PHARMAC P O Box 10-254 WELLINGTON Fax: (04) 460 4995 Phone: (04) 460 4990 Email: gaucherpanel@pharmac.govt.nz Date of Application: _________________________________________ Patient Name: NHI number: Date of…
SA0473 - Imiglucerase (Cerezyme) therapy - renewal application (4 pages, 67 KB)
Renewal application for imiglucerase (Cerezyme) therapy Send completed applications to: Gaucher Panel Co-ordinator PHARMAC P O Box 10-254 WELLINGTON Fax: (04) 460 4995 Phone: (04) 460 4990 Email: gaucherpanel@pharmac.govt.nz Date of Application: _________________________________________ Patient Name: NHI number: _________________________________________ Date of…
SA0855 – Multiple Sclerosis treatments, Initial Application for beta-interferon or glatiramer acetate (8 pages, 188 KB)
INITIAL APPLICATION FOR FUNDING OF BETA-INTERFERON OR GLATIRAMER ACETATE Please send applications to: The Co-ordinator MSTAC PHARMAC P O Box 10-254 WELLINGTON Phone: 04 460 4990 Facsimile: 04 916 7571 Email: mstaccoordinator@pharmac.govt.nz Applications must be complete and accompanied by all…
SA0855 – Multiple Sclerosis treatments, Renewal Application form for beta-interferon or glatiramer acetate (5 pages, 176 KB)
RENEWAL APPLICATION FOR FUNDING OF BETA-INTERFERON OR GLATIRAMER ACETATE For patients who are currently being treated with beta-interferon or glatiramer acetate (with New Zealand government funding) Please send applications to: The Co-ordinator MSTAC PHARMAC P O Box 10-254 WELLINGTON Phone:…
Active Special Authority numbers for atorvastatin (Lipitor) (2 pages, 489 KB)
By now you should have received information regarding the changes in access to atorvastatin being implemented from 1 June 2004. In essence these changes will result in patients that are on a dose below 40 mg of atorvastatin per day having their Special Authority cancelled.
Special Authority approvals for atorvastatin (Lipitor) (40 pages, 828 KB)
Listing of active Special Authority approvals for atorvastatin (Lipitor) from 1 June 2004 (other than approvals under the new criteria).